{"slug":"tirzepatide","seoKey":"tirzepatide","inn":"tirzepatide","displayName":"Tirzepatide","codes":["LY3298176","LY-3298176"],"synonyms":["GIP/GLP-1 dual receptor agonist","dual GIP and GLP-1 receptor agonist","twincretin (informal, not a technical term)"],"legalClass":"rx","identifiers":{"cas":"2023788-19-2","pubchemCid":166567236,"unii":"OYN3CCI6QE","inchikey":"BTSOGEDATSQOAF-MCNPHUAVSA-N","drugbankId":"DB15171","chemblId":"CHEMBL4297839","wikidataQid":"Q108324770","formula":"C225H348N48O68","molecularWeight":4813.53},"approvals":[{"market":"US","status":"approved_rx","date":"2022-05-13","note":"Prescription-only; indications: type 2 diabetes, cardiovascular risk reduction in type 2 diabetes, chronic weight management, obstructive sleep apnoea.","source":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0"},{"market":"EU","status":"approved_rx","date":"2022-09-15","note":"Centrally authorised, prescription-only; indications: type 2 diabetes, weight management.","source":"https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro"},{"market":"DE","status":"approved_rx","date":"2022-09-15","note":"Covered by the centralised EU authorisation; prescription-only. Weight management is excluded from statutory health insurance reimbursement.","source":"https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro"},{"market":"UK","status":"approved_rx","date":"2023-11-08","note":"Prescription-only medicine; indications: type 2 diabetes (authorised 2022) and weight management; the date shown is the weight-management authorisation.","source":"https://www.gov.uk/government/news/mhra-authorises-diabetes-drug-mounjaro-tirzepatide-for-weight-management-and-weight-loss"},{"market":"AU","status":"approved_rx","date":"2023-07-10","note":"Entered in the Australian Register of Therapeutic Goods; prescription-only; indications: type 2 diabetes, chronic weight management.","source":"https://www.tga.gov.au/resources/artg/379333"},{"market":"CA","status":"approved_rx","date":"2022-11-24","note":"Notice of Compliance issued; prescription-only; indication: type 2 diabetes.","source":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102974"},{"market":"CH","status":"approved_rx","date":"2022-11-02","note":"Prescription-only (dispensing category B); indications: type 2 diabetes and, by later extension, chronic weight management.","source":"https://www.swissmedic.ch/swissmedic/en/home/about-us/publications/public-summary-swiss-par/public-summary-swiss-par-mounjaro.html"}],"devStage":"approved","strongestEvidence":"rct_phase3","wada":{"status":"not_listed","listYear":2026,"source":"https://www.wada-ama.org/en/prohibited-list"},"trials":[{"nct":"NCT03954834","name":"SURPASS-1","phase":"Phase 3","n":478,"status":"COMPLETED"},{"nct":"NCT03987919","name":"SURPASS-2","phase":"Phase 3","n":1879,"status":"COMPLETED"},{"nct":"NCT03882970","name":"SURPASS-3","phase":"Phase 3","n":1444,"status":"COMPLETED"},{"nct":"NCT03730662","name":"SURPASS-4","phase":"Phase 3","n":2002,"status":"COMPLETED"},{"nct":"NCT04039503","name":"SURPASS-5","phase":"Phase 3","n":475,"status":"COMPLETED"},{"nct":"NCT04537923","name":"SURPASS-6","phase":"Phase 3","n":1428,"status":"COMPLETED"},{"nct":"NCT04255433","name":"SURPASS-CVOT","phase":"Phase 3","n":13299,"status":"COMPLETED"},{"nct":"NCT04184622","name":"SURMOUNT-1","phase":"Phase 3","n":2539,"status":"COMPLETED"},{"nct":"NCT04657003","name":"SURMOUNT-2","phase":"Phase 3","n":938,"status":"COMPLETED"},{"nct":"NCT04657016","name":"SURMOUNT-3","phase":"Phase 3","n":806,"status":"COMPLETED"},{"nct":"NCT04660643","name":"SURMOUNT-4","phase":"Phase 3 (randomised withdrawal)","n":670,"status":"COMPLETED"},{"nct":"NCT05822830","name":"SURMOUNT-5","phase":"Phase 3b","n":751,"status":"COMPLETED"},{"nct":"NCT05412004","name":"SURMOUNT-OSA","phase":"Phase 3","n":469,"status":"COMPLETED"},{"nct":"NCT04847557","name":"SUMMIT","phase":"Phase 3","n":731,"status":"COMPLETED"},{"nct":"NCT04166773","name":"SYNERGY-NASH","phase":"Phase 2","n":190,"status":"COMPLETED"}],"sameAs":["https://www.wikidata.org/wiki/Q108324770","https://pubchem.ncbi.nlm.nih.gov/compound/166567236","https://go.drugbank.com/drugs/DB15171","https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297839/"],"lastVerified":"2026-09-06","version":"1.0","published":true,"locale":"en","title":"Tirzepatide: what the trials show, status and safety","summary":"Tirzepatide is a laboratory-made peptide that imitates two of the gut hormones released after a meal, GIP and GLP-1, from a single molecule. It is an approved, prescription-only medicine in eight markets and was first authorised in May 2022. In its largest weight-loss trial, participants lost an average of 20.9% of their body weight over 72 weeks. In the big heart study it performed as well as an older drug, dulaglutide, but no better, and the US package inserts carry a prominent warning based on thyroid tumours found in rats.","updated":"2026-09-06","url":"https://mypep.app/peptides/tirzepatide"}